Results 31 to 40 of about 157,199 (404)

Glucose homeostasis changes and pancreatic β-cell proliferation after switching to cyclosporin in tacrolimus-induced diabetes mellitus

Nefrología (English Edition), 2015
Background: Switching to cyclosporin A may result in a reversion of tacrolimus-induced diabetes mellitus. However, mechanisms underlying such a reversion are still unknown.
Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres   +9 more
doaj   +1 more source

Association between time in therapeutic range of tacrolimus blood concentration and acute rejection within the first three months after lung transplantation

Journal of Pharmaceutical Health Care and Sciences, 2022
Background Tacrolimus is a key drug in immunosuppressive therapy following lung transplantation. The blood tacrolimus levels are likely to fluctuate in the early postoperative period, and failure to maintain the tacrolimus trough level in target ranges ...
Yoshiki Katada, Shunsaku Nakagawa, Kotaro Itohara, Takuya Suzuki, Ryota Kato, Hiroki Endo, Mitsuhiro Sugimoto, Atsushi Yonezawa, Takayuki Nakagawa, Akihiro Ohsumi, Daisuke Nakajima, Hiroshi Date, Tomohiro Terada   +12 more
doaj   +1 more source

The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients

Frontiers in Pharmacology, 2020
Tacrolimus is metabolized by CYP3A4 and CYP3A5 enzymes. Patients expressing CYP3A5 (in Caucasian patients about 15% of the population but more frequent in African Americans and Asians) have a dose requirement that is around 50% higher than non-expressers
T. van Gelder, S. Meziyerh, J. Swen, A. D. de Vries, D. Moes   +4 more
semanticscholar   +1 more source

What have we learned about primary liver transplantation under tacrolimus immunosuppression? - Long-term follow-up of the first 1000 patients [PDF]

, 1999
Objective: To summarize the long-term efficacy and safety of tacrolimus in orthotopic liver transplant (OLT) recipients, as well as to examine the factors that influence long-term morbidity and mortality rates. Background: Tacrolimus (FK506, Prograf) was
Abu-Elmagd, K, Fung, J, Jain, A, Kashyap, R, Reyes, J, Rohal, S, Starzl, T   +6 more
core   +2 more sources

Cambios en la homeostasis de la glucosa y la proliferación de la célula beta pancreática tras el cambio a ciclosporina en la diabetes inducida por tacrolimus

Nefrología, 2015
Antecedentes: El cambio a ciclosporina A podría revertir la diabetes inducida por tacrolimus. Sin embargo, los mecanismos de esta reversibilidad se desconocen. Métodos: Usamos como modelo de diabetes inducida por tacrolimus las ratas Zucker obesas.
Ana Elena Rodríguez-Rodríguez, Javier Triñanes, Esteban Porrini, Silvia Velázquez-García, Cecilia Fumero, María Jose Vega-Prieto, María Luisa Díez-Fuentes, Sergio Luis Lima, Eduardo Salido, Armando Torres   +9 more
doaj   +1 more source

Gene expression profiling to study racial differences after heart transplantation. [PDF]

, 2015
BackgroundThe basis for increased mortality after heart transplantation in African Americans and other non-Caucasian racial groups is poorly defined. We hypothesized that increased risk of adverse events is driven by biologic factors.
Anderson, Allen S, Baran, David A, Cotts, William G, Deng, Mario C, Ewald, Gregory A, Hiller, David, Kao, Andrew, Kfoury, Abdallah G, Khush, Kiran K, Pham, Michael X, Teuteberg, Jeffrey J, Valantine, Hannah A, Yee, James   +12 more
core   +2 more sources

Monitoring Intra-cellular Tacrolimus Concentrations in Solid Organ Transplantation: Use of Peripheral Blood Mononuclear Cells and Graft Biopsy Tissue

Frontiers in Pharmacology, 2021
Tacrolimus is an essential immunosuppressant for the prevention of rejection in solid organ transplantation. Its low therapeutic index and high pharmacokinetic variability necessitates therapeutic drug monitoring (TDM) to individualise dose.
Benedetta C. Sallustio, Benedetta C. Sallustio   +1 more
doaj   +1 more source

Exploratory Analysis of the Impact of an mHealth Medication Adherence Intervention on Tacrolimus Trough Concentration Variability: Post Hoc Results of a Randomized Controlled Trial

The Annals of Pharmacotherapy, 2020
Background: Medication nonadherence is a leading cause of late allograft loss in kidney transplantation (KT). Tacrolimus trough coefficient of variation (CV), measured using the coefficient of variation, is strongly correlated with acute rejection, graft
J. McGillicuddy, J. Chandler, L. Sox, D. Taber   +3 more
semanticscholar   +1 more source

Tacrolimus rescue therapy for renal allograft rejection - Five-year experience [PDF]

, 1997
Over the 5 year period from 7/14/1989 until 5/24/1994, we have attempted graft salvage with tacrolimus conversion in a total of 169 patients (median age 33 years, range 2-75 years) with ongoing rejection on baseline CsA immunosuppression after failure of
Demetris, AJ, Fung, JJ, Gritsch, HA, Jordan, ML, McCauley, J, McMichael, J, Naraghi, R, Randhawa, P, Scantlebury, VP, Shapiro, R, Smith, D, Starzl, TE, Vivas, CA   +12 more
core   +1 more source

Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury

Clinical pharmacology and therapy, 2020
Tacrolimus exhibits unpredictable pharmacokinetics (PKs) after lung transplant, partly explained by cytochrome P450 (CYP)–enzyme polymorphisms. However, whether exposure variability during the immediate postoperative period affects outcomes is unknown ...
T. Miano, Judd D. Flesch, R. Feng, Caitlin M. Forker, Melanie C. Brown, M. Oyster, L. Kalman, Melanie Rushefski, E. Cantu, M. Porteus, Wei Yang, A. Localio, J. Diamond, J. Christie, M. Shashaty   +14 more
semanticscholar   +1 more source